Genomic characterization of remission in juvenile idiopathic arthritis

Arthritis Research & Therapy

Kaiyu Jiang¹  Mark Barton Frank²  Yanmin Chen¹  Jeanette Osban²  James N Jarvis¹ 

[1] Department of Pediatrics, Rheumatology Research, SUNY Buffalo Clinical and Translational Research Center, 875 Ellicott Street, Buffalo, NY 14203

[2] Microarray Research Facility, Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, 840 NE 13th Street, Oklahoma City, OK 73104, USA

关键词: microarray;    biomarker;    gene expression;    TNF inhibitor;    methotrexate;    juvenile idiopathic arthritis;   

Others  :  1089040
DOI  :  10.1186/ar4280

【 摘 要 】

Introduction

The attainment of remission has become an important end point for clinical trials in juvenile idiopathic arthritis (JIA), although we do not yet have a full understanding of what remission is at the cell and molecular level.

Methods

Two independent cohorts of patients with JIA and healthy child controls were studied. RNA was prepared separately from peripheral blood mononuclear cells (PBMC) and granulocytes to identify differentially expressed genes using whole genome microarrays. Expression profiling results for selected genes were confirmed by quantitative, real-time polymerase chain reaction (RT-PCR).

Results

We found that remission in JIA induced by either methotrexate (MTX) or MTX plus a TNF inhibitor (etanercept, Et) (MTX + Et) is characterized by numerous differences in gene expression in peripheral blood mononuclear cells and in granulocytes compared with healthy control children; that is, remission is not a restoration of immunologic normalcy. Network analysis of the differentially expressed genes demonstrated that the steroid hormone receptor superfamily member hepatocyte nuclear factor 4 alpha (HNF4α) is a hub in several of the gene networks that distinguished children with arthritis from controls. Confocal microscopy revealed that HNF4a is present in both T lymphocytes and granulocytes, suggesting a previously unsuspected role for this transcription factor in regulating leukocyte function and therapeutic response in JIA.

Conclusions

These findings provide a framework from which to understand therapeutic response in JIA and, furthermore, may be used to develop strategies to increase the frequency with which remission is achieved in adult forms of rheumatoid arthritis.

【 授权许可】

   
2013 Jiang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Ringold S, Wallace CA: Measuring clinical response and remission in juvenile idiopathic arthritis. Curr Opin Rheumatol 2007, 19:471-476.
• [2]Jarvis JN: Juvenile rheumatoid arthritis: a guide for pediatricians. Pediatr Ann 2002, 31:437-446.
• [3]Shenoi S, Wallace CA: Remission in juvenile idiopathic arthritis: current facts. Curr Rheumatol Reports 2010, 12:80-86.
• [4]Wallace CA, Ruperto N, Giannini E, Childhood Arthritis and Rheumatology Research Alliance, Pediatric Rheumatology International Trials Organization, Pediatric Rheumatology Collaborative Study Group: Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004, 31:2290-2294.
• [5]Jarvis JN, Jiang K, Frank MB, Knowlton N, Aggarwal A, Wallace CA, McKee R, Chaser B, Tung C, Smith LB, McGhee JL, Chen Y, Osban J, O'Neil KN, Centola M: Gene expression profiling in neutrophils of children with polyarticular juvenile idiopathic arthritis. Arthritis Rheum 2009, 60:1488-1495.
• [6]Knowlton N, Jiang K, Frank MB, Aggarwal A, Wallace C, McKee R, Chaser B, Tung C, Smith L, Chen Y, Osban J, O'Neil K, Centola M, McGhee JL, Jarvis JN: The meaning of clinical remission in polyarticular juvenile idiopathic arthritis: gene expression profiling in peripheral blood mononuclear cells identifies distinct disease states. Arthritis Rheum 2009, 60:892-900.
• [7]Wallace CA, Huang B, Bandeira M, Ravelli A, Giannini EH: Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis Rheum 2005, 52:3354-3562.
• [8]Shenoi S, Wallace CA: Tumor necrosis factor inhibitors in the management of juvenile idiopathic arthritis: an evidence-based review. Paediatric Drugs 2010, 12:367-377.
• [9]Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He X, Maldonado-Cocco J, Orozco-Alcala J, Prieur AM, Suarez-Almazor ME, Woo P: International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision Edmonton, 2001. J Rheumatol 2004, 31:390-392.
• [10]Diehn M, Sherlock G, Binkley G, Jin H, Matese JC, Hernandez-Boussard T, Rees CA, Cherry JM, Botstein D, Brown PO, Alizadeh AA: SOURCE: a unified genomic resource of functional annotations, ontologies, and gene expression data. Nucleic Acids Research 2003, 31:219-223.
• [11]Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G: Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nature Genet 2000, 25:25-29.
• [12]Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JY, Zhang J: Bioconductor: open software development for computational biology and bioinformatics. Genome Biology 2004, 5:R80. BioMed Central Full Text
• [13]Piekorz RP, Nemetz C, Hocke GM: Members of the family of IL-6-type cytokines activate Stat5a in various cell types. Biochem Biophys Res Commun 1997, 236:438-443.
• [14]Huang Q, Jin X, Gaillard ET, Knight BL, Pack FD, Stoltz JH, Jayadev S, Blanchard KT: Gene expression profiling reveals multiple toxicity endpoints induced by hepatotoxicants. Mutat Res 2004, 549:147-167.
• [15]Kim YJ, Song M, Ryu JC: Inflammation in methotrexate-induced pulmonary toxicity occurs via the p38 MAPK pathway. Toxicology 2009, 256:183-190.
• [16]Sower LE, Froelich CJ, Allegretto N, Rose PM, Hanna WD, Klimpel GR: Extracellular activities of human granzyme A. Monocyte activation by granzyme A versus alpha-thrombin. J Immunol 1996, 156:2585-2590.
• [17]Takeda K, Akira S: STAT family of transcription factors in cytokine-mediated biological responses. Cytokine Growth Factor Rev 2000, 11:199-207.
• [18]Proskuryakov SY, Konoplyannikov AG, Gabai VL: Necrosis: a specific form of programmed cell death? Exp Cell Res 2003, 283:1-16.
• [19]Lovo E, Zhang M, Wang L, Ashton-Rickardt PG: Serine protease inhibitor 6 is required to protect dendritic cells from the kiss of death. J Immunol 2012, 188:1057-1063.
• [20]Sutherland CL, Chalupny NJ, Schooley K, VandenBos T, Kubin M, Cosman D: UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells. J Immunol 2002, 168:671-679.
• [21]Andreakos E, Sacre S, Foxwell BM, Feldmann M: The toll-like receptor-nuclear factor kappaB pathway in rheumatoid arthritis. Front Biosci 2005, 10:2478-2488.
• [22]Jarvis JN, Petty HR, Tang Y, Frank MB, Tessier PA, Dozmorov I, Jiang K, Kindzelski A, Chen Y, Cadwell C, Turner M, Szodoray P, McGhee JL, Centola M: Evidence for chronic peripheral activation of neutrophils in polyarticular juvenile rheumatoid arthritis. Arthritis Res Ther 2006, 8:R154. BioMed Central Full Text
• [23]Nakamura N, Shimaoka Y, Tougan T, Onda H, Okuzaki D, Zhao H, Fujimori A, Yabuta N, Nagamori I, Tanigawa A, Sato J, Oda T, Hayashida K, Suzuki R, Yukioka M, Nojima H, Ochi T: Isolation and expression profiling of genes upregulated in bone marrow-derived mononuclear cells of rheumatoid arthritis patients. DNA Res 2006, 13:169-183.
• [24]Goëb V, Thomas-L'Otellier M, Daveau R, Charlionet R, Fardellone P, Le Loët X, Tron F, Gilbert D, Vittecoq O: Candidate autoantigens identified by mass spectrometry in early rheumatoid arthritis are chaperones and citrullinated glycolytic enzymes. Arthritis Res Ther 2009, 11:R38. BioMed Central Full Text
• [25]Belinsky GS, Parke AL, Huang Q, Blanchard K, Jayadev S, Stoll R, Rothe M, Achenie LE, Gupta RR, Wu GY, Rosenberg DW: The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci 2007, 97:582-594.
• [26]Cyster JG, Goodnow CC: Tuning antigen receptor signaling by CD22: integrating cues from antigens and the microenvironment. Immunity 1997, 6:509-517.
• [27]Nitschke L, Carsetti R, Ocker B, Köhler G, Lamers MC: CD22 is a negative regulator of B-cell receptor signalling. Curr Biol 1997, 7:133-143.
• [28]Netea MG, Azam T, Ferwerda G, Girardin SE, Kim SH, Dinarello CA: Triggering receptor expressed on myeloid cells-1 (TREM-1) amplifies the signals induced by the NACHT-LRR (NLR) pattern recognition receptors. J Leukoc Biol 2006, 80:1454-1461.
• [29]Dower K, Ellis DK, Saraf K, Jelinsky SA, Lin LL: Innate immune responses to TREM-1 activation: overlap, divergence, and positive and negative cross-talk with bacterial lipopolysaccharide. J Immunol 2008, 180:3520-3534.
• [30]Modur V, Nagarajan R, Evers BM, Milbrandt J: FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer. J Biol Chem 2002, 277:47928-47937.
• [31]Renshaw SA, Parmar JS, Singleton V, Rowe SJ, Dockrell DH, Dower SK, Bingle CD, Chilvers ER, Whyte MK: Acceleration of human neutrophil apoptosis by TRAIL. J Immunol 2003, 170:1027-1033.
• [32]Wright HL, Moots RJ, Bucknall RC, Edwards SW: Neutrophil function in inflammation and inflammatory diseases. Rheumatology (Oxford) 2010, 49:1618-1631.
• [33]Grivennikov SI, Tumanov AV, Liepinsh DJ, Kruglov AA, Marakusha BI, Shakhov AN, Murakami T, Drutskaya LN, Förster I, Clausen BE, Tessarollo L, Ryffel B, Kuprash DV, Nedospasov SA: Distinct and nonredundant in vivo functions of TNF produced by t cells and macrophages/neutrophils: protective and deleterious effects. Immunity 2005, 22:93-104.
• [34]Salamone G, Giordano M, Trevani AS, Gamberale R, Vermeulen M, Schettinni J, Geffner JR: Promotion of neutrophil apoptosis by TNF-alpha. J Immunol 2001, (166):3476-3483.
• [35]van den Berg JM, Weyer S, Weening JJ, Roos D, Kuijpers TW: Divergent effects of tumor necrosis factor alpha on apoptosis of human neutrophils. J Leukoc Biol 2001, 69:467-473.
• [36]Cross A, Moots RJ, Edwards SW: The dual effects of TNFalpha on neutrophil apoptosis are mediated via differential effects on expression of Mcl-1 and Bfl-1. Blood 2008, 111:878-884.
• [37]Barbasi AL, Albert A: Emergence of scaling in networks. Science 1999, 286:509-512.
• [38]Jeong H, Tombor B, Oltval ZN, Barabasi A-L: The large-scale organization of metabolic networks. Nature 2000, 407:651-654.
• [39]Frank MB, Wang S, Aggarwal A, Knowlton N, Jiang K, Chen Y, McKee R, Chaser B, McGhee T, Osban J, Jarvis JN: Disease-associated pathophysiologic structures in pediatric rheumatic diseases show characteristics of scale-free networks seen in physiologic systems: implications for pathogenesis and treatment. BMC Med Genomics 2009, 2:9-23. BioMed Central Full Text
• [40]Odom DT, Zizlsperger N, Gordon DB, Bell GW, Rinaldi NJ, Murray HL, Volkert TL, Schreiber J, Rolfe PA, Gifford DK, Fraenkel E, Bell GI, Young RA: Control of pancreas and liver gene expression by HNF transcription factors. Science 2004, 303:1378-1381.
• [41]Ihara A, Yamagata K, Nammo T, Miura A, Yuan M, Tanaka T, Sladek FM, Matsuzawa Y, Miyagawa J, Shimomura I: Functional characterization of the HNF4alpha isoform (HNF4alpha8) expressed in pancreatic beta-cells. Biochem Biophys Res Commun 2005, 329:984-990.
• [42]Richard M, Drouin R, Beaulieu AD: ABC50, a novel human ATP-binding cassette protein found in tumor necrosis factor-alpha-stimulated synoviocytes. Genomics 1998, 53:137-145.
• [43]Wisniewski HG, Hua JC, Poppers DM, Naime D, VilEek J, Cronsteint BN: TNF/IL-1 -inducible protein TSG-6 potentiates plasmin inhibition by inter-alpha-inhibitor and exerts a strong anti-inflammatory effect in vivo. J Immunol 1996, 156:1609-1615.
• [44]Fujikado N, Saijo S, Iwakura Y: Identification of arthritis-related gene clusters by microarray analysis of two independent mouse models for rheumatoid arthritis. Arthritis Res Ther 2006, 8:R100. BioMed Central Full Text
• [45]Chiarini A, Armato U, Pacchiana R, DalPra I: Proteomic analysis of GTP cyclohydrolase 1 multiprotein complexes in cultured normal adult human astrocytes under both basal and cytokine-activated conditions. Proteomics 2009, 9:1850-1860.
• [46]Sanna MG, da Silva Correia J, Luo Y, Chuang B, Paulson LM, Nguyen B, Deveraux QL, Ulevitch RJ: ILPIP, a novel anti-apoptotic protein that enhances XIAP-mediated activation of JNK1 and protection against apoptosis. J Biol Chem 2002, 277:30454-30462.
• [47]Krieg A, Correa RG, Garrison JB, Le Negrate G, Welsh K, Huang Z, Knoefel WT, Reed JC: XIAP mediates NOD signaling via interaction with RIP2. Proc Natl Acad Sci USA 2009, 106:14524-14529.
• [48]Montfort A, de Badts B, Douin-Echinard V, Martin PG, Iacovoni J, Nevoit C, Therville N, Garcia V, Bertrand MA, Bessières MH, Trombe MC, Levade T, Benoist H, Ségui B: FAN stimulates TNF(alpha)-induced gene expression, leukocyte recruitment, and humoral response. J Immunol 2009, 183:5369-5378.
• [49]Cheung C, Akiyama TE, Kudo G, Gonzalez FJ: Hepatic expression of cytochrome P450s in hepatocyte nuclear factor 1-alpha (HNF1alpha)-deficient mice. Biochem Pharmacol 2003, 66:2011-2020.
• [50]Wang Z, Bishop EP, Burke PA: Expression profile analysis of the inflammatory response regulated by hepatocyte nuclear factor 4 α. BMC Genomics 2011, 12:128. BioMed Central Full Text
• [51]Li R, Pei H, Watson DK: Regulation of Ets function by protein-protein interactions. Oncogene 2000, 19:6514-6523.